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Abstract
Introduction: Radiation recall dermatitis is a well known but still poorly understood inflammatory
reaction. It can develop in previously irradiated areas and has been shown to be triggered by a
variety of different drugs, including cytostatic agents. Pemetrexed may cause radiation recall
dermatitis in pre-irradiated patients.
Case presentation: We present the case of a 49-year-old Caucasian woman with non-small cell
lung cancer who was initially treated with carboplatin and paclitaxel concomitant with radiotherapy
after suffering a painful plexus brachialis infiltration. Due to disease progression, a second-line
treatment with pemetrexed was started. A severe soft tissue necrosis developed despite steroid
treatment and plastic surgery.
Conclusion: To the best of our knowledge, we present the first case of a patient with severe soft
tissue necrosis in a pre-irradiated area after pemetrexed therapy. We believe that physicians
treating patients with pemetrexed should be aware of the severe, possibly life-threatening effects
that may be induced by pemetrexed after previous radiation therapy.
Introduction
Radiation recall dermatitis is a well known but still poorly
understood inflammatory reaction that can develop in
previously irradiated sites, and can be triggered by a vari-
ety of different drugs, including cytostatic agents such as
gemcitabine, taxanes or anthracyclines [1-3]. Two case
reports of radiation recall dermatitis after administration
of pemetrexed have been published, but neither caused
extensive soft tissue necrosis [4,5]. The most frequent site
of radiation recall is the skin, but radiation recall reactions
have also been reported to affect the brain, the lungs and
the gastrointestinal-system [6-8]. The interval between
radiation therapy and onset of radiation recall dermatitis
is variable, however, more severe reactions have been
described towards the completion of radiation therapy
[9]. Radiation recall dermatitis may also develop without
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clinically apparent prior radiation toxicity. The aetiology
of radiation recall dermatitis is still unknown. It is nor-
mally a self-limiting reaction without long-term sequelae.
Case presentation
A 49-year-old Caucasian woman presented with stage IV
squamous cell lung cancer (cT4 N3 M1, multiple pulmo-
nary lesions). She had a smoking history of 20 pack years.
Palliative chemotherapy was initiated with carboplatin
AUC 3 and paclitaxel 75 mg/m2, on days 1, 8 and 15, and
repeated every 28 days. Radiation therapy for painful left-
sided plexus brachialis infiltration with partial arm paresis
was performed concurrently during cycle two and three. A
total dose of 39 Gy was administered in 13 fractions with
6× photons over a total treatment time of 2.5 weeks. A
conformal plan with equally weighted opposing fields
from antero-posterior and postero-anterior was used.
During radiotherapy, the patient developed typical symp-
toms of radiation dermatitis. The initially dry maculopa-
pular rash and pruritus worsened one week after
completion of radiotherapy to National Cancer Institute
Common Toxicity Criteria (NCI-CTC) grade 3 with ery-
thema and small ulcerations in the medio-scapular and
cervical left radiation fields. The acute dermatitis resolved
within three weeks after application of local and systemic
steroids. The subsequent chemotherapy cycles did not
cause any further dermal problems and resulted in a par-
tial response after a total of six cycles.
Three months later, the pulmonary metastases progressed
and a new adrenal mass was detected on her right side.
Second-line chemotherapy with pemetrexed (Alimta,
multitargeted antifolate, Eli Lilly) was proposed. The first
pemetrexed dose of 500 mg/m2 was given eight months
after completion of radiation therapy with standard pre-
medication of folic acid, vitamin B12 and dexametha-
sone. After the first dose, the patient reported increasing
dysaesthesia in the former radiation area, however, no
skin reaction was detected on clinical examination. The
second dose of pemetrexed, given three weeks later, led to
massive dermatitis one week after the second infusion in
the area of the former radiation field, strictly restricted to
the back and sparing the front side of the radiation field.
Direct tumour infiltration of the skin was excluded by skin
biopsy. The diagnosis of radiation recall dermatitis was
suggested and pemetrexed was stopped.
Despite immediate local and systemic treatment with ster-
oids (60 mg of prednisone) and antibiotics (amoxicillin),
a progressive necrosis of the skin and underlying soft tis-
sue developed over the following two weeks (Figure 1)
causing massive pain and immobilisation of the left
shoulder and arm. A surgical debridement of the necrosis
and a musculus latissimus dorsi flap from the contralat-
eral side as well as additional primary coverage with a
cutaneous mesh craft were performed. The muscle flap
became necrotic and in a second operation, the flap had
to be removed. The large tissue defect showed no signs of
improvement despite intensive local wound care. On the
contrary, continuous destruction occurred with involve-
ment of the scapula (Figure 2). Due to the ongoing necro-
sis with deteriorating condition of the patient, we
abstained from further chemotherapy. Sixteen months
after the chemotherapy had been stopped, the patient
died of uncontrolled local infection and concurrent pneu-
monia.
Discussion
This case demonstrates unexpected and extremely severe
radiation recall dermatitis with soft tissue necrosis. Peme-
trexed was the probable cause as this was the only new
drug used at the time of the developing radiation recall
dermatitis. There are two known previous cases with
much less severe radiation recall dermatitis in patients
treated with pemetrexed [4,5]. In the first case, the patient
had been treated 25 years before with adjuvant radiother-
apy for breast cancer before receiving second-line treat-
ment with pemetrexed for a non-small cell lung cancer
(NSCLC). In the other case, the patient had received cispl-
atin and pemetrexed after having received radiotherapy
with 21 Gy for a mesothelioma. Indeed our patient had
received a higher dose of radiation therapy (39 Gy versus
21 Gy) and the interval between radiation therapy and
exposure to pemetrexed was shorter (8 months versus 25
years) than in the abovementioned cases. This may serve
as a possible explanation for the massive reaction we
observed.
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Conclusion
Pemetrexed is becoming increasingly used in second-line
treatment for NSCLC [5], often in patients with prior radi-
ation therapy. We therefore believe that physicians treat-
ing patients with pemetrexed need to be aware of this
severe treatment-caused complication. After the first dose
of pemetrexed, the patient described slight discomfort
with dysaesthesia, and after the second dose, the full-
blown clinical symptoms developed. Not only careful
examination and assessment by experienced clinicians
but also the awareness of recall dermatitis due to peme-
trexed may prevent new cases occurring.
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